Put companies on watchlist
SYNBIOTIC SE
ISIN: DE000A3E5A59
WKN: A3E5A5
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

SYNBIOTIC SE · ISIN: DE000A3E5A59 · EQS - Company News (32 News)
Country: Germany · Primary market: Germany · EQS NID: 1909827
23 May 2024 10:31AM

SYNBIOTIC and CEO Daniel Kruse on roadshow


EQS-News: SYNBIOTIC SE / Key word(s): Miscellaneous
Berlin, Prague, Berlin: SYNBIOTIC and CEO Daniel Kruse on roadshow

23.05.2024 / 10:31 CET/CEST
The issuer is solely responsible for the content of this announcement.


The leading European industrial hemp and cannabis group SYNBIOTIC is increasing its public presence. "We want to be even more visible and approachable in the professional world and for our investors," explains Daniel Kruse, CEO of SYNBIOTIC. "The aim is to position the enormous potential of hemp in the centre of society. It's time to end the demonisation of cannabis."

The end of the "noise clause"

Cem Özdemir, Federal Minister of Food and Agriculture, announced an important step in this direction in a virtually historic speech at the Parliamentary Evening of the Cannabis Industry on 14 May 2024 in Berlin, in the presence of Daniel Kruse. Özdemir wants to ensure that the so-called "intoxication clause" is removed. This special German rule currently means that even very low concentrations of THC in industrial hemp can lead to criminal liability, raids and business closures. According to Özdemir, the current reluctance to address the issue is "almost like giving bakeries or even the entire bakery trade a wide berth just because they sell poppy seed cake." "The cancellation of the 'intoxication clause' would be an initial spark for industrial hemp in Germany. Sales would suddenly multiply!" predicts Kruse.

EIHA - Let's Talk Hemp

SYNBIOTIC is taking part in the 21st conference of the European Industrial Hemp Association (EIHA) in Prague. On 6 and 7 June 2024, the European Who's Who of industrial hemp will meet in the Czech capital. Daniel Kruse will open the conference at the renowned Prague Congress Centre as President of EIHA and, as CEO of SYNBIOTIC, has been invited to take his place on the podium as a speaker. His topics will focus on the (new) legal framework for industrial hemp in Germany and the global market potential for hemp foods. SYNBIOTIC is also the main sponsor of the Expo taking place at the same time and will be represented with an exhibition stand.

Mary Jane - Expo, conference and festival

From Prague, it's straight back to Berlin. From 14 to 16 June 2024, SYNBIOTIC will be presenting itself as a leading European industrial hemp and cannabis company group at Mary Jane, Germany's most significant cannabis expo. SYNBIOTIC will be exhibiting here for the first time together with Bushdoctor - a subsidiary of the SYNBIOTIC Group since December 2023. Stands B25 and B26, each measuring 36 m², are independent but directly connected to each other. The SYNBIOTIC team will be on site with eight employees and will be available to answer questions from investors, consumers and interested parties. Bushdoctor will offer its complete sales programme on site in Berlin - from seeds and hemp plants for cultivation to CBD products and smoking accessories. Customers can buy directly or via discounted online orders at the trade fair.

Daniel Kruse, CEO of SYNBIOTIC, will be taking part in two panel discussions at the Mary Jane conference. On Friday, 14 June 2024 on the topic "Is it worth growing hemp now? The Need for an Industrial Hemp Law" and on Saturday, 15 June 2024 on "Global Industrial Networking - How Can We Accelerate a Long-Term Change in Strategy?"

Publisher
SYNBIOTIC SE
Daniel Kruse, CEO
Münsterstrasse 336
40470 Düsseldorf
Germany

Media contact
Rüdiger Tillmann
SYNBIOTIC
Public Relations Manager
E-mail ruediger.tillmann@synbiotic.com
Mobile +49 170 9651451
c/o JOLE.group

About SYNBIOTIC
SYNBIOTIC is a listed group of companies in the hemp and cannabis sector and pursues a buy and build investment strategy focussed on the EU. The group covers the entire value chain from cultivation to production and retail - from the field to the shelf. The core businesses of the vertically integrated company are research and development, production and commercialisation of hemp, CBD and cannabis products. SYNBIOTIC has a clear strategy to further expand along the value chains of its business areas - hemp and CBD, medical cannabis and consumer cannabis.


23.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: SYNBIOTIC SE
Münsterstr. 336
40470 Dusseldorf
Germany
E-mail: office@synbiotic.com
Internet: https://www.synbiotic.com/
ISIN: DE000A3E5A59
WKN: A3E5A5
Listed: Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt, Munich, Tradegate Exchange
EQS News ID: 1909827

 
End of News EQS News Service

1909827  23.05.2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1909827&application_name=news&site_id=boersengefluester~~~ace3d64b-2049-452a-8d18-fbc8044c4b5f
Visual performance / price development - SYNBIOTIC SE
Smart analysis and research tools can be found here.

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.